RxDoctor Payments Data

Barry Lowell, MD

Cardiovascular Disease · Mount Arlington, NJNPI 1780735563

Payments from drug & device makers

$20,991in general payments, 2019–2025

Across 1,221 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Medtronic$2K
  • Novartis$1K
  • Boston Scientific$1K
  • Johnson & Johnson$1K
  • Pfizer$997
  • plus $11K from 53 others

What the payments were for

  • Travel & lodging$1,7548%
  • Food & beverage$19,09591%
  • Education$1421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk203$2,492
Medtronic(2 entities)22$2,213
Novartis147$1,413
Boston Scientific19$1,373
Johnson & Johnson104$1,282
Pfizer75$997
Abbott28$905
Sanofi-aventis U.S. LLC53$886
Amgen72$840
Boehringer Ingelheim53$739
Corcept Therapeutics34$708
Bayer40$703
AstraZeneca48$698
Merck47$636
Abiomed11$597
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)21$466
Lilly USA, LLC32$455
E.r. Squibb & Sons, L.L.C.28$444
Alnylam Pharmaceuticals Inc.16$276
Baxter Healthcare10$259
Amarin Pharma, Inc.16$229
Esperion Therapeutics, Inc.14$214
Philips North America LLC7$156
Lexicon Pharmaceuticals, Inc.8$142
Kiniksa Pharmaceuticals, Ltd.10$142
Lundbeck LLC10$134
Shockwave Medical, Inc1$131
Irhythm Technologies, Inc.6$124
Impulse Dynamics (USA) Inc.6$113
Kiniksa Pharmaceuticals International, PLC7$108
GSK7$95
Heartflow, Inc.4$93
Cvrx, Inc.6$88
Regeneron Healthcare Solutions, Inc.7$87
Bridgebio Pharma, Inc.4$76
Kowa Pharmaceuticals America, Inc.4$59
Cardiovascular Systems Inc.5$58
Arbor Pharmaceuticals, Inc.4$53
United Therapeutics Corporation3$51
Scpharmaceuticals Inc.3$49
Actelion Pharmaceuticals US, Inc.3$48
Chiesi USA, Inc.3$44
Vivus LLC2$30
Acist Medical Systems, Inc.1$26
Althera Pharmaceuticals LLC2$23
Edwards Lifesciences1$21
Atricure, Inc.1$21
Angiodynamics, Inc.1$21
Recor Medical Inc1$20
Bardy Diagnostics, Inc.2$19
Cashflow Solutions, LLC1$18
Kestra Medical Technology Services, Inc.1$17
Exact Sciences1$17
Cardiva Medical, Inc.1$14
Celonova Biosciences, Inc.1$14
AbbVie1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
Hikma Pharmaceuticals USA1$13
Currax Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,991 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$438,992
Medicare patients
1,530
Services billed
5,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide880$1,101,446
MounjaroTirzepatide716$937,553
JardianceEmpagliflozin518$704,728
XareltoRivaroxaban515$601,817
EliquisApixaban351$421,111
ArcalystRilonacept13$304,430
VyndamaxTafamidis12$264,206
EntrestoSacubitril/Valsartan186$255,351
FarxigaDapagliflozin Propanediol193$242,084
Repatha SureclickEvolocumab193$195,690
MultaqDronedarone Hcl44$93,631
TrulicityDulaglutide41$70,537
BrilintaTicagrelor43$36,166
Rosuvastatin Calcium1,829$28,603
KerendiaFinerenone20$27,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,492$1,101,446880 claims
Lilly USA, LLCMounjaro, Trulicity$455$1,008,091757 claims
Boehringer IngelheimJardiance$739$704,728518 claims
PfizerEliquis, Vyndamax$997$685,317363 claims
Johnson & JohnsonXarelto$1,282$601,817515 claims
Kiniksa Pharmaceuticals International, PLCArcalyst$108$304,43013 claims
AstraZenecaFarxiga, Brilinta$698$278,249236 claims
NovartisEntresto$1,413$255,351186 claims
Sanofi-aventis U.S. LLCMultaq$886$93,63144 claims
BayerKerendia$703$27,57220 claims
GSKTrelegy Ellipta$95$23,47523 claims
MerckJanumet Xr$636$10,66125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Mount Arlington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →